ML327 is primarily used in biochemical and pharmacological research as a selective inhibitor of the mitochondrial pyruvate carrier (MPC). By inhibiting MPC, ML327 disrupts the transport of pyruvate into mitochondria, thereby altering cellular metabolism. This property makes it a valuable tool for studying metabolic reprogramming in cancer cells, as many tumor cells rely on aerobic glycolysis and mitochondrial metabolism for growth and survival. Researchers use ML327 to investigate how metabolic shifts affect cell proliferation, apoptosis, and response to therapies. It has shown potential in sensitizing cancer cells to other treatments by compromising their metabolic flexibility. Additionally, ML327 is employed in studies related to diabetes and neurodegenerative diseases, where mitochondrial function and substrate utilization play critical roles. Its application remains confined to laboratory research, particularly in cell culture and animal models, aiding the development of metabolism-targeted therapeutics.